Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts
YAO Kai-Hu, JIA Ju
National Center for Children's Health/Beijing Children's Hospital, Capital Medical University/Beijing Pediatric Research Institute/National Key Discipline of Pediatrics(Capital Medical University)/National Clinical Research Center for Respiratory Diseases/Key Laboratory of Major Diseases in Children, Ministry of Education/Beijing Key Laboratory of Pediatric Respiratory Infectious Diseases, Beijing 100045, China
Abstract On November 3, 2017, the China Food and Drug Administration reported that the potency indexes of two batches of diphtheria-pertussis-tetanus vaccines produced by two companies did not reach the requirements. Insufficient potency could affect the protection effect of these vaccines immunization. Currently, pertussis cases have already showed an increasing trend in China and could last for several years. Such an increase could be linked to these adverse events of vaccine with insufficient potency, which could become an evidence to challenge or deny the effectiveness of vaccination, and brings a persistent inhibition of the public's acceptance for vaccination. The wider global context of pertussis resurgence, previous underestimate on the domestic pertussis, the promotion of detection methods, the change of knowledge about pertussis, the confirmation of pertussis in elder children and adults, the antigenicity variation of pertussis strains could lead to a significant increase of pertussis cases. Health researchers and clinical workers should raise awareness about these factors, and assess rationally the impact of vaccine titer deficiency on pertussis epidemiology for maintaining and promoting public confidence in vaccination.
YAO Kai-Hu,JIA Ju. Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts[J]. CJCP, 2018, 20(1): 1-4.
YAO Kai-Hu,JIA Ju. Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts[J]. CJCP, 2018, 20(1): 1-4.
Domenech de Cellès M, Magpantay FM, King AA, et al. The pertussis enigma:reconciling epidemiology, immunology and evolution[J]. Proc Biol Sci, 2016, 283(1822):20152309.
Yang Y, Yao K, Ma X, et al. Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970-2014)[J]. PLoS One, 2015, 10(9):e0138941.
Diavatopoulos DA, Cummings CA, Schouls LM, et al. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica[J]. PLoS Pathog, 2005, 1(4):e45.
[16]
Mooi FR. Bordetella pertussis and vaccination:the persistence of a genetically monomorphic pathogen[J]. Infect Genet Evol, 2010, 10(1):36-49.
[17]
Souder E, Vodzak J, Evangelista AT, et al. Antimicrobial susceptibility and molecular detection of pertactin-producing and pertactin-deficient Bordetella pertussis[J]. Pediatr Infect Dis J, 2017, 36(1):119-121.
